The exaggerated inflammatory response in Behçet's syndrome: Identification of dysfunctional post-transcriptional regulation of the IFN?/CXCL10 (IP-10) pathway by Ambrose, N et al.
1 
 
 
THE EXAGGERATED INFLAMMATORY RESPONSE IN BEHÇET’S 
SYNDROME: IDENTIFICATION OF DYSFUNCTIONAL POST-
TRANSCRIPTIONAL REGULATION OF THE IFN/CXCL10 (IP-10) 
PATHWAY. 
 
Nicola Ambrose 
1
, Emon Khan 
1
,  Rahul Ravindran,
 1
 Liz Lightstone 
2
,
 
Sonya Abraham 
2
, 
Marina Botto 
2
, Michael Johns 
1
, Dorian Haskard 
1*
  
 
1
 Vascular Sciences Section, National Heart and Lung Institute; and 
2 
Divion of Immunology and 
Inflammation, Imperial College, London, UK 
 
* Correspondence to Professor Dorian Haskard, d.haskard@imperial.ac.uk 
 
 
 
ACKNOWLEDGEMENTS AND STATEMENT OF FINANCIAL SUPPORT 
NA was an Arthritis Research UK-funded Fellow. Our study was also made possible by funding 
through the British Heart Foundation and the NIHR Biomedical Research Centre at Imperial College 
Healthcare NHS Trust.  DOH received professorial core support from the British Heart Foundation. 
We would like to extend our gratitude to all volunteers who participated, and in particular to the UK 
Behçet’s Syndrome Society. No financial support or benefits were obtained from commercial sources. 
The authors have no conflicts of interest to declare. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
ABSTRACT 
The mechanisms underlying the exaggerated inflammatory response in Behçet’s Syndrome (BS) 
remain poorly understood.  
Objectives:  We investigated the response of CD14+ blood monocytes to IFNfocusing on the 
chemokine CXCL10.   
Methods: Chemokine synthesis and release were analysed at a protein and mRNA level following 
stimulation with IFN. Findings in BS patients were compared with 25 healthy controls (HC), 15 
rheumatoid arthritis (RA) and 15 systemic lupus erythematosus (SLE) disease control patients.   
Results: BS monocytes produced significantly more CXCL10 protein than HC monocytes from two 
hours following IFNγ stimulation, despite equivalent quantities of mRNA, suggesting more efficient 
translation. This was significantly more pronounced in BS with high disease activity and in those with 
ocular and neurological clinical manifestations. The imbalance between CXCL10 protein and mRNA 
expression was not observed in either RA or SLE patients, and was not seen with other chemokines 
studied (CXCL9, CXCL11 and CCL2).  Furthermore, BS monocytes treated with an alternative 
stimulant (LPS) did not show abnormal TNFreleaseSucrose density gradients to segregate 
monocyte CXCL10 mRNA into free RNA or polysome-associated RNA showed equal proportions in 
BS and HC samples, suggesting that the difference between BS and HC may be due to reduced 
negative control of CXCL10 translation in BS.  
Conclusions BS monocytes have dysfunctional post-transcriptional regulation of CXCL10 mRNA, 
resulting in overexpression of CXCL10 protein upon IFNγ stimulation.  As CXCL10 is a chemokine 
that recruits mononuclear cells, this abnormality may contribute to the exaggerated inflammatory 
responses that characterises BS. 
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BACKGROUND 
Behçet’s Syndrome (BS)  is a chronic, multisystem disorder, typically characterised by orogenital 
ulcerations and uveitis but potentially affecting most organs [1]. Although the pathogenesis of BS 
remains relatively poorly understood, recent genome wide association studies have highlighted a 
number of susceptibility loci including HLA B51, IL-10 and IL23R-IL12RB2 [2, 3].  A working 
model is that BS is a polygenic condition with environmental triggers (possibly viral), being 
characterised clinically by exaggerated and prolonged inflammatory reponses (eg pathergy).  A skew 
towards Th1 cytokine production has been reported [4-6]. 
Chemokines are low molecular weight cytokines primarily responsible for chemotaxis of either 
specific leukocytes or groups of leukocytes [7]. CXCL10, along with the closely related chemokines 
CXCL9 and CXCL11, is an IFNγ-inducible agonist for the CXCR3 chemokine receptor, which is 
rapidly induced on naıve T cells following activation, and remains highly expressed by Th1 CD4+ T 
cells, effector CD8+ T cells and innate-type lymphocytes, such as NK and NKT cells [8, 9].  
The potential contribution of the IFNγ induced chemokine axis to the pathogenesis of BS has been 
suggested by previous studies. High levels of IFNγ were found in BS aqueous humour fluid compared 
with other forms of uveitis [10].  Moreover, high levels of CXCL9, 10 and 11 have been observed in 
serum from BS uveitis patients, and high CXCL10 protein was found in CSF fluid of BS subjects [11, 
12]. CXCR3 receptors (the receptor for CXCL9/10/11) have been shown to be highly expressed in BS 
biopsies of oral ulcers [13].  Moreover, the pathology of pathergy reactions shows increased mRNA 
transcripts for CXCR3, CXCL10 and CXCL11 [14, 15].  Given the likely importance of CXCL10 in 
BS, this project investigated the generation of CXCL10 in response to IFN in CD14+ blood 
monocytes.  
 
METHODS 
The study was conducted according to the principles of the Declaration of Helsinki and all participants 
gave written informed consent. Ethical approval was obtained from the local Research Ethics 
Committee. 
Subject recruitment and evaluation  
Both male and female individuals aged over 18 years were included. Subjects with significant co-
morbidities were excluded. BS subjects were recruited from the Hammersmith Hospital Rheumatology 
Clinic, and via the UK Behçet’s Syndrome Society. All subjects satisfied the 1990 ISG Behçet 
Diagnostic Criteria [16]. A clinical history including medication history was obtained and disease 
activity was assessed using the Leeds Behçet's Disease Activity Form, which gives an activity score on 
a 0-12 point scale. We classified patients as having an inactive / low diseae activity score (DAS) (< 4) 
or higher activity ( >4) [17]. Age- and sex-matched healthy control (HC) volunteers were recruited 
locally and were required to be free of significant acute or chronic inflammatory disease, and not to be 
on medications (women taking oral contraception were not excluded). Rheumatoid arthritis (RA) 
subjects fulfilled the 2010 American College of Rheumatology (ACR) / European League Against 
Rheumatism (EULAR) criteria for RA [18]. A clinical history including medication history was 
obtained and disease activity was quantified using DAS28 (ESR) scoring which gives a score on a 1-
10 point scale (with >5.1 indicating active disease)[19]. Systemic lupus erythematosus (SLE) subjects 
fulfilled the ACR criteria for SLE [20]. A clinical history including medication history was obtained 
and disease activity was quantified using the SLE disease activity score (SLEDAI) which gives a score 
on a 1-105 point scale (with >6 indicating active disease)[20]. 
Monocyte isolation and culture 
Mononuclear cells were isolated from peripheral venous blood using Histopaque (Sigma Aldrich, 
UK). They were re-suspended and incubated in 80µL buffer (PBS with 0.5% BSA and 0.5M EDTA 
(Sigma-Aldrich)) and 20µL CD14 microbeads (Miltenyi, Germany) per 10
7
 cells. CD14+ monocytes 
were then positively selected on a MS column (Miltenyi). Cells were plated at 10
6
/ml in DMEM 
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(Invitrogen, UK) with 10% fetal calf serum (FCS) (Biosera, UK) and 1% penicillin-streptavidin 
(Sigma-Aldrich, UK). Cell purity was confirmed as 98% by flow cytometry. 
Enzyme-linked immunosorbent assays (ELISA) 
Concentrations of inflammatory mediators were determined by capture ELISA using matched 
antibody pairs (DuoSet; R&D Systems, Abingdon, UK) according to the manufacturer’s 
recommendations. Optical Densities (OD) were determined using a microplate reader set to 450nm. 
Standard curves for each cytokine (in duplicate) were generated by using the reference cytokine 
concentrations supplied in the kits. All samples were measured in duplicate and the results were 
calculated against the standard curve, and expressed as the mean ± SEM cytokine concentration (pg or 
ng/ml). 
RNA extraction, cDNA generation and quantitative real-time PCR  
An RNeasy easy kit (Qiagen), Trizol RNA, or Trizol LS RNA extraction methods were used to isolate 
RNA. For Trizol RNA extraction, cells were homogenized with 1mL of Trizol Reagent (Invitrogen, 
UK). The samples were incubated for 5 min at room temperature. Chloroform was then added and 
samples vortexed for 15 secs. Following incubation for 2-3 min, samples were centrifuged at 12,000g 
for 15 min at 4
 o
C to separate the mixture. The upper aqueous phase, containing RNA, was separated 
into a fresh tube and RNA precipitated by adding isopropyl alcohol. Samples were then incubated at 
room temperature for 10 min and centrifuged at 12,000 x g for 10 min at 4°C. The supernatant was 
completely removed and the RNA pellet was washed twice with 75% ethanol followed by drying at 
37°C for 5-10 min. RNA was then dissolved in 20µL RNase free water (Sigma). The purity and the 
concentration of the RNA were analysed using a Nanodrop spectrophotometer (Thermo Scientific). 
DNA-Free (Ambion, UK) was used to purify the sample. cDNA was synthesised using the 
SuperScript® III RT kit (Invitrogen) following manufacturer’s instructions. Quantitative real-time 
PCR was undertaken using SYBR green fastmix IQ (Quanta perfecta, Invitrogen); and the following 
primers: CXCL9 F5' TTG CTG GTT CTG ATT GGA GTG 3'; R 5' CCT TGG TTG GTG CTG ATG 
C 3'; CCL-2 F5' AGT CAC CTG CTG TTA T 3', R 5' TCA AGT CTT CGG AGT T 3'; CXCL10 F5' 
GCT ATG TTC TTA GTG GAT GTT C3', R 5' AGG ATG GCA GTG GAA GTC 3'; HPRT F 5' TTG 
GTC AGG CAG TAT ATT CC 3', R GGG CAT ATC CTA AA CA AC 3', Oligo dt 5' CGA CTC 
GAG TCG ACA TCG ATT TTT TTT TTT TTT TT 3'.  Real-time PCR were performed using the 
iCycler thermocycler (Biorad). On completion of the first qRT-PCT run for each new primer set, the 
product was validated with an agarose gel. Results were expressed as a ratio of the test signal to the 
house-keeper gene HPRT. During set up experiments results were also validated using other 
housekeepers (GAPDH and actin).  
Sucrose density gradient testing 
A 50-20% discontinuous sucrose gradient was prepared in Polyallomer tubes (Beckman Coulter, 
USA). Cell lysates were added and the sample was then ultracentifuged at 150,000g for 90 min at 4
o 
C. 
The material was then extracted in 1 ml fractions, after which each fraction was ‘spiked’ with a known 
quantity of GFP mRNA before RNA purification, cDNA conversion and RT-PCR analysis. The GFP 
spike was used to normalise values to account for any loss of product during processing.  
Statistical methodology  
Analyses were carried out using PRISM software.  The data are presented as medians and inter-
quartile ranges unless otherwise stated. Mann-Whitney non parametric testing was used to compare 
two outcomes. Kruskal-Wallis was used for non parametric testing for multiple groups, or where 
required, Dunn’s test was used to correct for multiple non-parametric comparisons.  
 
RESULTS 
Demographics  
Twenty seven BS subjects, 25 HC, 15 RA and 15 SLE subjects donated samples for in vitro work. 
There were three rounds of subject recruitment to answer consecutive questions. The demographic 
data, clinical characteristics, disease activity and medication use of these three cohorts is listed in 
Supplementary Tables 1-3.  
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Comparison of CXCL10 expression by blood monocytes in BS and HC 
In pilot experiments, 20 ng/ml was found to be the lowest concentration of IFNγ that elicited a robust 
expression of CXCL10. Monocytes from cohort 1 BS subjects were found to produce significantly 
more CXCL10 protein in response to IFNthan those from HC at both 2 hours (p=0.005) and 4 hours 
(p<0.001) (Figure 1A). In contrast, no difference was observed between groups in the quantity of 
mRNA measured (Figure 1B). To test whether the increased CXCL10 protein production was due to 
immediate or delayed release, we performed a second experiment using cohort 2, examining earlier 
time-points. This confirmed the increased CXCL10 protein expression from BS monocytes, and 
showed that this was not evident before two hours following IFNγ treatment (p=0.027) (Figure 1C). 
As before, there was no difference between BS and HC in CXCL10 mRNA expression (Figure 1D).  
Pooling data from the 2 hour time-points in these two experiments, we plotted CXCL10 protein 
production against CXCL10 mRNA and found the slopes to be significantly different, as analysed by 
linear regression (F=12.5829, DFn=1, DFd=65, p<0.001, linear regression analysis) (Figure 1E,F). 
Taken together, these data suggest that the mechanism responsible for increased CXCL10 protein 
expression in BS is post-transcriptional. 
Relation between CXCL10 expression and BS disease activity and disease characteristics 
A significant difference was observed in CXCL10 protein between HC and BS, regardless of BS 
disease activity (DAS <4, p <0.05; DAS >4, p <0.05) (Figure 2A).  Whilst there was no significant 
difference in CXCL10 protein expression by monocytes from BS with low versus high activity, we 
were able to demonstrate a significant difference between the low versus high activity groups when 
the protein to mRNA expression was compared (p<0.05) (Figure 2B).  This indicated that the 
CXCL10 protein to mRNA ratio may relate to disease activity. Connections between clinical 
manifestations and CXCL10 expression were then assessed. Those in the mucocutaneous group (MC) 
were free of cardiovascular (CV), ocular (OC) or neurological (NEU) involvement. Analysis of 
variance of CXCL10 protein concentration showed a significant variance between the groups 
(p<0.001), with a NEU and OC BS subjects having significantly higher CXCL10 expression than HC 
(p<0.05) (Figure 2C).  The sizes of the clinical subgroups were not sufficient to allow statistical 
evaluation of differences in protein to mRNA ratio between specific groups. Nevertheless, there was a 
trend towards having a higher protein to mRNA ratio with the OC and NUE groups, and, in contrast, 
the HC and the limited mucocutaneous groups closely resembled each other (Figure 2D). These results 
indicate that BS patients with neurological and ocular manifestaions have exgaggerated CXCL10 
protein expression in contrast to those with limited mucocutaneous subjects.   
Comparison of CXCL10 expression by blood monocytes in BS versus RA and SLE 
To determine whether the increase in CXCL10 protein secretion was particular to BS patients, we 
compared a further BS cohort (cohort 3) with patients with RA or SLE.  CXCL10 protein 
concentrations were greater following IFNγ stimulation in the supernatant of BS samples than those of 
RA (p<0.005) or SLE (p<0.005) subjects, whereas no differences were observed at the mRNA level 
(Figure 3).  
Comparison of CXCL10 expression by blood monocytes in BS versus other chemokines 
We evaluated CXCL9, CXCL11 (chemokines closely related to CXCL10) and CCL2 protein 
production following IFNγ stimulation in HC and BS subjects using samples from cells stimulated for 
two hours with IFN from the pooled cohorts, as in Suppl. Table 4.  We were unable to detect 
significant CXCL11 protein production in these samples. Both HC and BS monocyte supernatants 
contained CCL2, with no difference between groups (data not shown). Supernatants from BS patients 
contained significantly more CXCL9 than those from HC (Figure 4A), but in contrast to CXCL10 
results, there was also a statistically significant increase the mRNA level in the BS samples, 
suggesting a closer transcription-translation relationship (Figure 4B).  When the CXCL9 and CXCL10 
protein to mRNA plots were compared (Figure 4C,D), CXCL10 showed greater protein:mRNA 
disparity (p<0.05). 
Comparison of TNF expression by blood monocytes in BS compared to other groups following 
LPS stimulation 
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We also tested whether monocytes from BS subjects secrete more TNF than those from other groups 
following stimulation with LPS (20ng/ml) for two hours. Monocytes from most individuals 
demonstrated a robust response, but there were no differences either in TNF protein or mRNA 
expression between groups (Figure 5).  
Polysome profiling to assess post-transcriptional regulation of IFNγ - CXCL10 
To further investigate translational efficiency in BS and HC, sucrose density gradient analysis was 
undertaken to assess CXCL10 mRNA polysomal association. For this experiment, we re-recruited the 
three BS subjects with the highest CXCL10 protein to mRNA ratios and the three HCs with the lowest 
CXCL10 protein to mRNA ratios. There was no statistically significant difference between HC and 
BS CXCL10 mRNA polysomal association despite higher expression of CXCL10 protein in the BS 
subjects (Supplementary Figure 1), indicating that the more efficient translation was not dependent on 
increased polysomal association, and therefore involved translational regulation at the post-initiation 
level.   
 
DISCUSSION 
The IFNγ – CXCL10 pathway is of interest to us as IFNγ appears to be an important cytokine in BS 
and CXCL10 has been found in excess in uveitis, CSF and histological samples of BS [10-15]. We 
found increased CXCL10 protein expression by IFN-stimulated monocytes in repeated experiments 
comparing BS and HC. As this difference was not matched by differences in CXCL10 mRNA, the 
abnormality is likely to be post-transcriptional. It is notable that its detection required functional 
analysis of monocytes, and the abnormailuty could not readily have been predicted by genomic 
investigations.   
The increased expression of CXCL10 by BS monocytes was only observed at 2 hours and after, 
indicating that it relates to more efficient new protein synthesis rather than increased release from 
intracellular stores. This is consistent with previous reports that CXCL10 is not stored intracellularly, 
but is rapidly secreted following synthesis [21].  By performing sucrose density centrifugation, we 
found that there was no difference between BS and HC in the proportion of CXCL10 mRNA in free 
versus polysome fractions. This suggests that the reason for the increased CXCL10 protein expression 
is not due to differential translational initiation, but more likely due to more efficient translation within 
polysomes. We hypothesise that this is due to reduced presence of a regulatory microRNA species 
normally suppressing CXCL10 mRNA translation [22, 23], but this obviously requires further study.  
To investigate the clinical relevance of our findings we correlated CXCL10 expression with disease 
activity scores (DAS) and clinical characteristics. There was a significant difference between high 
DAS and other goups when results were plotted as protein to mRNA ratio. Additionally, we were 
interested to find that CXCL10 protein expression correlated most strongly with neurological or ocular 
manifestations. This is in keeping with high CXCL10 levels previously observed in such patients [12, 
24].   
Our study has some limitations. First, all patient groups consisted of individuals taking a wide variety 
of medications. However, if medications had accounted for the observations, we might have seen a 
suppressed rather than exaggerated response in patients compared to non-medicated healthy controls. 
group. Furthermore, patients with RA and SLE were on as much medication as those with BS, if not 
more. Secondly, our patient numbers were not powered to find statistical significance in correlations 
with DAS or clinical subtypes and it would be interesting to undertake a larger study to properly 
address this question. Thirdly, we did not include a HC group in our comparison of BS with RA and 
SLE, and so we are unable to state whether or not CXCL10 expression by monocytes in normal in 
these disease control groups.  
 
To our knowledge, this approach to investigating cytokine protein synthesis has not been undertaken 
in an inflammatory disease before.  Our findings show an ‘uncoupling’ in the mRNA to protein ratio 
in BS, and highlight CXCL10 as an affected chemokine.  It will be interesting to determine what other 
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genes are similarly overexpressed at the protein synthesis level in BS, and to find out whether they 
collectively contribute to the exaggerated inflammatory response that characterises this disorder. 
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Figure 1.  Behçet's Syndrome monocytes overexpress CXCL10 protein but not mRNA following 
IFNMonocytes from healthy controls (HC) and Behçet's Syndrome subjects (BS) (cohort 1) 
were stimulated with IFNγ (20ng/ml):  (A) CXCL10 protein secretion and (B) CXCL10 mRNA after 2 
and 4 hours.  Significantly more CXCL10 protein was produced at both 2 hours (p <0.005) and 4 hours 
(p<0.001) by BS monocytes but there was no difference in CXCL10 mRNA between the two groups. 
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(C, D) The experiment was repeated using cohort 2 BS and HC, with measurements at earlier time-
points over 2 hours. A significant difference was again observed at the 2 hour time point in CXCL10 
protein levels (p = 0.027) but not in CXCL10 mRNA. (E, F) CXCL10 protein production plotted 
against mRNA using the 2 hour time-points in both experiments: (E) HC and (F) BS. The slopes are 
significantly different (p<0.001). 
 
Figure 2. Relation between monocyte CXCL10 expression and BS disease activity CXCL10 
data from BS monocytes stimulated with IFN (20 ng/ml) for 2 hours were assessed in relation 
to disease activity score (DAS).  (A) Shows that CXCL10 protein expression was similarly 
increased in those with low versus high DAS, whereas in (B) the disparity between protein and 
mRNA expression is greater in patients with high DAS (p<0.05). (C, D) CXCL10 expression 
was related to clinical manifestations. There was a significant difference between CXCL10 
protein in HC versus ocular (OC) (p<0.05) and neurological (NEU) (p<0.05) BS samples, and 
the same trend was seen when CXCL10 protein to mRNA levels were plotted. In contrast no 
significant difference was observed between CXCL10 expression in HC and mucocutaneous 
(MC) or cardiovascular (CV) BS samples. 
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Figure 3. Behçet's Syndrome monocytes express more CXCL10 protein than those from 
patients with RA and SLE. Monocytes from patients with BS (cohort 3), RA or SLE were 
stimulated with IFNγ (20ng/ml): (A) CXCL10 protein, and (B) CXCL10 mRNA. CXCL10 
protein expression was greater in BS monocytes than in those from RA (p<0.005) or SLE 
(p<0.005) subjects. There were no significant differences in mRNA levels.  
 
 
Figure 4. Expression of CXCL9 protein and mRNA from IFN-stimulated monocytes. 
Monocytes from patients with BS or HC were stimulated with IFNγ (20ng/ml): (A) CXCL9 
protein in BS was significantly greater than HC (p<0.005), (B) CXCL9 mRNA expression was 
also significantly greater (p<0.05). (C, D) CXCL9 (C) and CXCL10 (D) protein production 
plotted against mRNA. For CXCL9, the slopes for BS and HC were similar, and the slope for 
BS CXCL10 was significantly greater than for CXCL9 (BS dashed lines, HC solid lines; 
p<0.05).  
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Figure 5.  Expression of TNFα in monocytes stimulated with LPS. Monocytes from patients 
with BS, RA or SLE or from HC were stimulated with LPS (20ng/ml) for two hours. There 
were no differences in either TNF protein secretion or mRNA expression between groups.  
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Supplementary figure 1: Polysomal association study of CXCL10 mRNA 
 
 
Supplementary Figure 1. CXCL10 mRNA shows a similar association with polysomes in BS and HC 
despite differences in protein production: (A) A representative voltage tracing of polysome factions 
within a sucrose density gradient passing though under laser over time. The far left of the trace 
represents free total RNA and later segments represent total RNA associated with ribosomal subunits 
and polysomes. (B) The percentage occupancy of CXCL10 mRNA. CD14+ monocytes from BS (n=3) and 
HC (n=3) stimulated for 2 hours with IFNγ (20μL/mL). Samples 1&2 represent free RNA. There was no 
statistically significant difference between HC and BS. (C) CXCL10 protein expression in HC and BS 
subjects (n=3).  (D-E) Comparison of free and polysomal mRNA in (a) unstimulated or (b) stimulated 
monocytes. There was no statistically significant difference between HC and BS, supporting the finding 
that despite different quantities of protein being produced by the two groups, there was no change in 
polysomal association between the groups.  
 
 
